Ernst N, Friedrich M, Bieber K, Kasperkiewicz M, Gross N, Sadik C D, Zillikens D, Schmidt E, Ludwig R J, Hartmann K
Luebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany.
Center for Research on Inflammation of the Skin, University of Luebeck, Luebeck, Germany.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):486-492. doi: 10.1111/jdv.16780. Epub 2020 Jul 20.
Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are common autoimmune bullous dermatoses (AIBD) characterized by blisters and erosions. Treatment options are limited and often insufficient. Immune checkpoint receptors play critical roles in immune homoeostasis and self- tolerance. Targeting checkpoint receptors is highly efficient in treatment of various cancers, but often also associated with autoimmune side effects.
We therefore aimed to investigate the expression of immune checkpoint receptors in patients with BP and PV.
We analysed expression of the checkpoint receptors programmed cell death protein 1 (PD-1), T-cell immunoglobulin and mucin domain 3 (Tim-3) and lymphocyte activation gene 3 (Lag-3) in lesional skin of patients with BP and PV compared to healthy control skin as well as the expression patterns of PD-1 and Tim-3 on various infiltrating immune cells in skin sections of AIBD by immunohistochemistry and immunofluorescence. We also measured serum levels of soluble PD-1, Tim-3 and Lag-3 in AIBD patients by ELISA.
We report on increased expression of PD-1 and Tim-3, but not Lag-3, in lesional skin of patients with BP and PV. Investigating the expression pattern of PD-1 and Tim-3 on different cutaneous immune cells, we observed significant upregulation of PD-1 predominantly on infiltrating CD8 T cells and upregulation of Tim-3 on CD8 T cells as well as macrophages.
Our results suggest exploring immune checkpoint receptors as novel therapeutic targets using an agonistic approach in autoimmune bullous diseases.
大疱性类天疱疮(BP)和寻常型天疱疮(PV)是常见的自身免疫性大疱性皮肤病(AIBD),其特征为水疱和糜烂。治疗选择有限且往往效果不佳。免疫检查点受体在免疫稳态和自身耐受中起关键作用。靶向检查点受体在各种癌症的治疗中高效,但也常常伴有自身免疫性副作用。
因此,我们旨在研究BP和PV患者中免疫检查点受体的表达情况。
我们通过免疫组织化学和免疫荧光分析了BP和PV患者皮损皮肤中与健康对照皮肤相比的检查点受体程序性细胞死亡蛋白1(PD-1)、T细胞免疫球蛋白和粘蛋白结构域3(Tim-3)以及淋巴细胞激活基因3(Lag-3)的表达,以及AIBD皮肤切片中各种浸润免疫细胞上PD-1和Tim-3的表达模式。我们还通过酶联免疫吸附测定法(ELISA)测量了AIBD患者血清中可溶性PD-1、Tim-3和Lag-3的水平。
我们报告了BP和PV患者皮损皮肤中PD-1和Tim-3表达增加,但Lag-3未增加。在研究PD-1和Tim-3在不同皮肤免疫细胞上的表达模式时,我们观察到PD-1主要在浸润的CD8 T细胞上显著上调,而Tim-3在CD8 T细胞以及巨噬细胞上上调。
我们的结果表明,在自身免疫性大疱性疾病中使用激动剂方法探索免疫检查点受体作为新的治疗靶点。